Are Options Traders Bullish on ALLO?
Let daily Option Order Flow show you where stock investors are Bullish and Bearish!!! Receive a FREE daily email of the Market Chameleon Order Flow Sentiment Newsletter.
Market Chameleon

Please Login or Register

Login|Register FREE

Please Login or Register

Login|Register FREE

About ALLO

Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) therapies for cancer. Led by a world-class management team with significant experience in cell therapy, Allogene is developing a pipeline of "off-the-shelf" CAR T cell therapy candidates with the goal of delivering readily available cell therapy faster, more reliably and at greater scale to more patients. AlloCAR T cell therapies are engineered from cells of healthy donors, which is intended to allow for creation of inventory for on demand use in patients. This approach is designed to eliminate the need to create personalized therapy from a patient's own cells, simplify manufacturing, and reduce the time patients must wait for CAR T cell treatment. The Allogene portfolio includes rights to 16 pre-clinical CAR T cell therapy targets and UCART19, an AlloCAR T therapy candidate currently in Phase 1 sponsored by Servier for the treatment of relapsed/refractory acute lymphoblastic leukemia (ALL).
Primary Exchange: NASDAQ
SIC Biological Products, (No Diagnostic Substances)
NAICS Biological Product (except Diagnostic) Manufacturing

ALLO is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
ONEQ Fidelity Nasdaq Composite Index Tracking Stock 1.7 B 1.7E+09 1,022 1022 0.02% 0.000234621 413 K 412594

Wait, Before You Leave...